Safety of Anal Curcumin

Last updated: April 17, 2025
Sponsor: Lisa Flowers
Overall Status: Active - Recruiting

Phase

1

Condition

Precancerous Condition

Lung Cancer

Genitourinary Cancer

Treatment

Curcumin

Curcuminoid Capsules

Clinical Study ID

NCT06626230
STUDY00007193
  • Ages > 30
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.

Eligibility Criteria

Inclusion

Major Inclusion Criteria:

  • 30 and older

  • Have biopsy-proven anal intraepithelial neoplasia (AIN) 2, AIN 3 without previoustreatment

  • Or cytology results for ASC-H or HSIL

  • Able and willing to complete Study Diary

  • Other inclusion criteria apply

Exclusion

Exclusion Criteria:

  • Have a clinically significant chronic medical condition that is consideredprogressive, such as but not limited to coronary disease, congestive heart failure,chronic obstructive lung disease, and diabetes mellitus. Chronic nonprogressive orintermittent syndromes are not excluded, including migraine headaches, mild reactiveairway disease, controlled hypertension, stable pain syndromes, or benign gastricreflux.

  • Have any history of anal cancer malignancy.

  • Pregnant or planning to become pregnant in the next three months.

  • Have a history of sensitivity or allergy to any compound used in this study.

  • Have Grade 2 or higher renal or hematology abnormality,

  • Are currently using, or in the last year have used intravenous drugs (except fortherapeutic use), recreational drugs, or alcohol abuse.

  • Other exclusion criteria apply

Study Design

Total Participants: 48
Treatment Group(s): 2
Primary Treatment: Curcumin
Phase: 1
Study Start date:
March 17, 2025
Estimated Completion Date:
January 31, 2026

Study Description

This proposal suggests conducting a Phase I clinical trial using a 3 + 3 dose escalation approach to assess the safety and determine the maximum tolerated dose of intra-anal curcumin in individuals with HIV who have anal high-grade squamous intraepithelial lesions (aHSIL/AIN 2-3). Currently, there is a significant need for non-surgical treatments for pre-malignant anal diseases in people with HIV, aiming to reduce risks and complications associated with existing surgical and topical interventions.

Curcumin, a compound derived from turmeric, is known for its anti-inflammatory and anti-infectious properties. While previous research has shown its anticancer effects in oral doses, its bioavailability is limited, and intra-anal administration has not been studied in humans. This trial aims to explore the potential of intra-anal curcumin as an alternative treatment for aHSIL in people with HIV.

The study will involve enrolling participants with aHSIL and administering increasing doses of curcumin intra-anally for 14 days, following the 3 + 3 dose escalation model. The trial will continue until the dose-limiting toxicity (DLT) level is reached, and participants report symptoms necessitating a dose reduction.

To enhance future studies, the researchers will also evaluate patient and male partner acceptability through questionnaires. The insights gained from this trial will guide the design of subsequent efficacy and safety studies for individuals with AIN 2 and 3 neoplasia.

Connect with a study center

  • Grady Hospital - Ponce De Leon Clinic

    Atlanta, Georgia 30308
    United States

    Active - Recruiting

  • Grady Memorial Hospital

    Atlanta, Georgia 30303
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.